Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | IDH1 |
| Variant | act mut |
| Impact List | unknown |
| Protein Effect | gain of function |
| Gene Variant Descriptions | IDH1 act mut indicates that this variant results in a gain of function in the Idh1 protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
IDH1 mutant IDH1 act mut |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03471260 | Phase Ib/II | Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Recruiting | USA | 0 |
| NCT03914742 | Phase Ib/II | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | Completed | USA | 0 |
| NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
| NCT02925234 | Phase II | Niraparib Tepotinib Erdafitinib Ivosidenib Panitumumab Pemigatinib | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |